Drug Type CAR-T |
Synonyms BCMA-CD19 CAR-T therapy(Peking University People's Hospital), BCMA-CD19 Targeted Chimeric Antigen Receptor T-Cell(Peking University People's Hospital) |
Target |
Action modulators |
Mechanism BCMA modulators(B-cell maturation protein modulators), CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | China | 26 Dec 2024 | |
Antiphospholipid Syndrome | Phase 2 | China | 26 Dec 2024 | |
Behcet Syndrome | Phase 2 | China | 26 Dec 2024 | |
Immunoglobulin G4-Related Disease | Phase 2 | China | 26 Dec 2024 | |
Myositis | Phase 2 | China | 26 Dec 2024 | |
Scleroderma, Diffuse | Phase 2 | China | 26 Dec 2024 | |
Sjogren's Syndrome | Phase 2 | China | 26 Dec 2024 | |
Systemic Lupus Erythematosus | Phase 2 | China | 26 Dec 2024 | |
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | China | 26 Dec 2024 |